TELO: Telomir Pharmaceuticals, Inc. Forward P/S Multiple

Telomir Pharmaceuticals (TELO) - corporate logo

The bet on radical longevity through Telomir Pharmaceuticals (TELO) R&D is confirmed by the dynamics of the expected P/S valuation, where the value expresses the state of the metric. Telomir Pharmaceuticals (TELO) focuses on treating anemia and pulmonary fibrosis while penetrating the anti-aging market. Since the business relies on external financing without current sales, this chart demonstrates speculative demand for future technological breakthroughs.

TELO Telomir Pharmaceuticals, Inc.: Price-to-Projected Revenue Ratio in the range 07/04/2022 - 11/16/2026

Summary analytical data breakdowns for Telomir Pharmaceuticals (TELO)

Comprehensive company analysis:TELO (Telomir Pharma)
Original product of Telomir Pharmaceuticals Corp

Telomir Pharmaceuticals (TELO) laboratory diversification minimizes logistical risks in drug development, ensuring a stable stream of future revenues. This forward price-to-sales ratio compares the current market value of the business with expected sales volumes, allowing investors to assess the asset's overvaluation and the probability of a correction should actual performance deviate from calculated models.

Key competitors

Forward P/S Multiple HLN (Haleon PLC)|Forward P/S Multiple Kenvue Corp KVUE|Verona Pharma PLC - Forward P/S Multiple|Market Cap to Future Revenue Ratio jyongbio.com|LGND: Forward P/S Multiple|Market Cap to Projected Revenue AMRX|Price-to-Projected Revenue Ratio Perrigo Company|Market Cap to Future Revenue Ratio Alvotech ALVO|Forward P/S Multiple LQDA|GLPG: Future Price to Revenue|Forward P/S Multiple ANIP (ANI Pharmaceuticals, Inc.)|Market Cap to Expected Sales Ratio MannKind Corp (MNKD)|AMPH: Forward Price-to-Revenue Multiple|Forward Price to Sales PCRX (Pacira)|ARS Pharmaceuticals (SPRY) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue TBPH|AQST (Aquestive Corp) - Forward P/S Multiple|Forward Price-to-Revenue Multiple scPharmaceuticals Inc. (SCPH)|Forward Price-to-Revenue Multiple TECX (Tectonic Therapeutic, Inc.)|TNXP (Tonix Pharmaceuticals Holding) - Forward Price to Sales|Price-to-Projected Revenue Ratio SXT Pharmaceuticals SXTC|Forward Price to Sales EPRX|BHST - Price-to-Projected Revenue Ratio|eXoZymes (EXOZ) - Forward Price-to-Revenue Multiple|ORMP: Forward P/S Multiple|ENTX: Price to Expected Revenue Ratio|HYFT (ipatherapeutics.com) - Forward P/S Multiple|Forward P/S Multiple ABVC BioPharma|Price-to-Projected Revenue Ratio Cumberland Pharmaceuticals Inc. (CPIX)|QNTM (Quantum BioPharma Ltd.) - Forward Price to Sales|Forward P/S Multiple FGEN (fibrogen.com)|RANI - Forward Price-to-Revenue Multiple|SNYR - Price-to-Projected Revenue Ratio|rallybio.com - Price to Expected Revenue Ratio|LEXX: Forward P/S Multiple|Forward Price-to-Revenue Multiple Pulmatrix Inc|PTHL (Pheton Holdings) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Aptorum Group Limited APM|Price-to-Projected Revenue Ratio Lyra Therapeutics (LYRA)|Forward Price-to-Revenue Multiple Impact BioMedical Inc IBO|Price-to-Projected Revenue Ratio tnfpharma.com TNFA|Forward Price to Sales YCBD|PainReform Ltd - Forward P/S Multiple|Altamira Therapeutics Ltd (CYTO) - Forward Price-to-Revenue Multiple|lipella.com (LIPO) - Price-to-Projected Revenue Ratio|OptiNose (OPTN) - Forward P/S Multiple|PIRS (Pieris Pharmaceuticals Inc) - Forward P/S Multiple|PROC: Forward Price to Sales|Price-to-Projected Revenue Ratio Petros Pharmaceuticals, Inc. (PTPI)|Forward P/S Multiple Qilian International Corp (QLI)|ACELYRIN, Inc. - Forward Price-to-Revenue Multiple|Forward P/S Multiple tffpharma.com TFFP